E²

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

👉https://www.linkedin.com/events/itwdrivandeweber-cofounder-ceoa7258560211001511937/theater/

Exciting news! 🚀 Join us for the next episode of our LinkedIn Live podcast featuring Dr. Ivan De Weber, PhD Weber, co-founder and CEO of Cortex Discovery, a groundbreaking startup revolutionizing drug discovery through AI!

🔬 From Academia to AI-Powered Drug Discovery

Dr. de Weber's journey is nothing short of inspiring. We'll explore his transition from cellular biology and pharmaceutical bioinformatics to founding a company at the cutting edge of AI-driven drug discovery. Learn how his lifelong quest for longevity research led to the creation of Cortex Discovery.

🧠 Unveiling Cortex Discovery's Innovative Approach

Discover how Cortex Discovery is disrupting preclinical drug discovery across all therapeutic areas with their proprietary AI models. We'll delve into:

• Their foundation model for drug property predictions

• The vast database of 750 million data points powering their deep learning system

• Recent breakthroughs, including the first AI-discovered compound proven to extend lifespan in a whole organism

💼 Business Insights and Future Outlook

Get an insider's perspective on:

• Cortex Discovery's unique business model and collaboration opportunities

• Challenges faced in the AI-driven drug discovery landscape

• The company's vision for the future of longevity research and pharmaceutical development

This episode is a must-watch for:

• Biotech and pharmaceutical executives

• Investors in the life sciences sector

• Academic researchers in pharmaceutical chemistry, longevity biology, and clinical medicine

• Anyone interested in the intersection of AI and drug discovery

Don't miss this opportunity to gain valuable insights into the future of AI-powered drug discovery and longevity research. Tune in to our LinkedIn Live podcast and be part of the conversation shaping the future of medicine!

👉https://www.linkedin.com/events/itwdrivandeweber-cofounder-ceoa7258560211001511937/theater/

Hosted on Acast. See acast.com/privacy for more information.

👉https://www.linkedin.com/events/itwdrivandeweber-cofounder-ceoa7258560211001511937/theater/

Exciting news! 🚀 Join us for the next episode of our LinkedIn Live podcast featuring Dr. Ivan De Weber, PhD Weber, co-founder and CEO of Cortex Discovery, a groundbreaking startup revolutionizing drug discovery through AI!

🔬 From Academia to AI-Powered Drug Discovery

Dr. de Weber's journey is nothing short of inspiring. We'll explore his transition from cellular biology and pharmaceutical bioinformatics to founding a company at the cutting edge of AI-driven drug discovery. Learn how his lifelong quest for longevity research led to the creation of Cortex Discovery.

🧠 Unveiling Cortex Discovery's Innovative Approach

Discover how Cortex Discovery is disrupting preclinical drug discovery across all therapeutic areas with their proprietary AI models. We'll delve into:

• Their foundation model for drug property predictions

• The vast database of 750 million data points powering their deep learning system

• Recent breakthroughs, including the first AI-discovered compound proven to extend lifespan in a whole organism

💼 Business Insights and Future Outlook

Get an insider's perspective on:

• Cortex Discovery's unique business model and collaboration opportunities

• Challenges faced in the AI-driven drug discovery landscape

• The company's vision for the future of longevity research and pharmaceutical development

This episode is a must-watch for:

• Biotech and pharmaceutical executives

• Investors in the life sciences sector

• Academic researchers in pharmaceutical chemistry, longevity biology, and clinical medicine

• Anyone interested in the intersection of AI and drug discovery

Don't miss this opportunity to gain valuable insights into the future of AI-powered drug discovery and longevity research. Tune in to our LinkedIn Live podcast and be part of the conversation shaping the future of medicine!

👉https://www.linkedin.com/events/itwdrivandeweber-cofounder-ceoa7258560211001511937/theater/

Hosted on Acast. See acast.com/privacy for more information.

👉https://www.linkedin.com/events/itwdrivandeweber-cofounder-ceoa7258560211001511937/theater/

Exciting news! 🚀 Join us for the next episode of our LinkedIn Live podcast featuring Dr. Ivan De Weber, PhD Weber, co-founder and CEO of Cortex Discovery, a groundbreaking startup revolutionizing drug discovery through AI!

🔬 From Academia to AI-Powered Drug Discovery

Dr. de Weber's journey is nothing short of inspiring. We'll explore his transition from cellular biology and pharmaceutical bioinformatics to founding a company at the cutting edge of AI-driven drug discovery. Learn how his lifelong quest for longevity research led to the creation of Cortex Discovery.

🧠 Unveiling Cortex Discovery's Innovative Approach

Discover how Cortex Discovery is disrupting preclinical drug discovery across all therapeutic areas with their proprietary AI models. We'll delve into:

• Their foundation model for drug property predictions

• The vast database of 750 million data points powering their deep learning system

• Recent breakthroughs, including the first AI-discovered compound proven to extend lifespan in a whole organism

💼 Business Insights and Future Outlook

Get an insider's perspective on:

• Cortex Discovery's unique business model and collaboration opportunities

• Challenges faced in the AI-driven drug discovery landscape

• The company's vision for the future of longevity research and pharmaceutical development

This episode is a must-watch for:

• Biotech and pharmaceutical executives

• Investors in the life sciences sector

• Academic researchers in pharmaceutical chemistry, longevity biology, and clinical medicine

• Anyone interested in the intersection of AI and drug discovery

Don't miss this opportunity to gain valuable insights into the future of AI-powered drug discovery and longevity research. Tune in to our LinkedIn Live podcast and be part of the conversation shaping the future of medicine!

👉https://www.linkedin.com/events/itwdrivandeweber-cofounder-ceoa7258560211001511937/theater/

Hosted on Acast. See acast.com/privacy for more information.

LLMs vs. NLP: A Clarification

Understanding the AI Landscape

Artificial Intelligence (AI) has made significant strides in recent years, especially in the field of natural language processing (NLP). A particular subset of NLP, Large Language Models (LLMs), has garnered much attention due to their impressive capabilities. However, it's important to understand the relationship between these two concepts.

NLP: The Foundation

Natural Language Processing (NLP) is a branch of AI that focuses on the interaction between computers and human language. It encompasses various techniques that enable machines to understand, interpret, and generate human language. NLP tasks include:

Text Analysis: Breaking down text into smaller units, such as words and sentences.

Sentiment Analysis: Determining the emotional tone of text, whether it's positive, negative, or neutral.

Machine Translation: Translating text from one language to another.

Text Summarization: Condensing long pieces of text into shorter summaries.

Question Answering: Providing answers to questions posed in natural language.

LLMs: A Powerful Tool

Large Language Models (LLMs) are a specific type of AI model that has been trained on massive amounts of text data. This training enables them to generate human-quality text, translate languages, write different kinds of creative content, and answer your questions in an informative way. LLMs are a powerful tool within the NLP toolkit, but they are not a replacement for all NLP techniques.

The Relationship Between LLMs and NLP

To clarify the relationship between LLMs and NLP, consider the following analogy:

NLP is like a toolbox filled with various tools, each designed for specific tasks.

LLMs are a powerful tool within this toolbox, capable of performing a wide range of tasks, but they are not the only tool available.

While LLMs excel at tasks like text generation and question answering, traditional NLP techniques may be more suitable for other tasks, such as sentiment analysis or information extraction.

The Broader AI Landscape

Both NLP and LLMs are subsets of a larger field, Machine Learning (ML). ML is a branch of AI that involves training algorithms on data to make predictions or decisions. Other key branches of ML include:

Computer Vision: Enabling machines to understand and interpret visual information.

Reinforcement Learning: Training agents to make decisions by interacting with an environment.

Unsupervised Learning: Discovering hidden patterns in data without explicit labels.

Conclusion

LLMs are a significant advancement in the field of NLP, but they are not a replacement for all NLP techniques. Instead, they complement and enhance the existing tools available to AI researchers and developers. By understanding the relationship between LLMs and NLP, we can better appreciate their potential and limitations, and apply them effectively to solve real-world problems.

Hosted on Acast. See acast.com/privacy for more information.

ITW Kamyar Maserrat - Intellectual Property Lawyer | Senior Counsel at Foley & Lardner LLP | Expert in Deeptech

🚀 Unveiling the Future of Deep Tech: Join Us for an Exclusive Chat with IP Guru Kamyar Maserrat! 🚀

🌟 Calling all scientists, engineers, tech startup founders, and VCs! 🌟

Are you ready to dive into the thrilling world of deep tech and intellectual property? We've got an episode that you absolutely CANNOT miss! 🎬

Join us for an electrifying conversation with Kamyar Maserrat, Senior Counsel at Foley & Lardner LLP and a true IP wizard in the realms of AI, robotics, and quantum tech. Kamyar's journey from civil engineer to leading IP lawyer is nothing short of inspiring, and his insights are pure gold for anyone navigating the complex landscape of deep tech innovation.

💡 Why You Need to Watch This Episode:

Unraveling IP Complexity: Kamyar breaks down the intricate world of intellectual property, making it accessible and actionable for startups and innovators.

AI and Quantum Revolution: Discover the latest trends and challenges in AI and quantum technology, and how they're reshaping the future of tech.

Strategic IP Advantage: Learn how a robust IP strategy can be your secret weapon in securing venture capital funding and gaining a competitive edge.

Global IP Chess Game: Get insider tips on navigating the global IP landscape and protecting your innovations across borders.

Future of IP in Deep Tech: Kamyar shares his predictions on the future of IP in deep tech, including collaborative IP models and the role of AI in the patent process.

🎯 Who Should Watch:

Tech Startup Founders: Gain invaluable insights into protecting your innovations and attracting investors.

Scientists and Engineers: Understand the legal landscape of deep tech and how to safeguard your groundbreaking work.

Venture Capitalists: Learn what to look for in a startup's IP portfolio to make smarter investment decisions.

This episode is a must-watch for anyone looking to stay ahead in the fast-paced world of deep tech. Whether you're a seasoned entrepreneur or an aspiring innovator, Kamyar's expertise will equip you with the knowledge and strategies you need to succeed.

For more insights into the world of IP law and deep tech, be sure to check out Kamyar's blog, "Beyond the Binary," at Foley & Lardner LLP. And for a deeper dive into the fascinating world of quantum technology, Kamyar recommends the book "Quantum Supremacy" by Michio Kaku.

Kamyar's LinkedIn

https://www.linkedin.com/in/kamyar-maserrat-6118908/

Beyond The Binary: https://www.foley.com/insights/publications/2024/04/beyond-binary-legal-considerations-quantum-computing-era/

Hosted on Acast. See acast.com/privacy for more information.